AL
ALNY.US Alnylam Pharmaceuticals Inc
- Market cap
- USD 22.1B
- P/E
- 8.3x
- P/B
- 5.82x
- ROE
- 93.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ALNY.US undervalued?
Graham numberALNY.US trades 46.9% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Alnylam Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Alnylam Pharmaceuticals Inc yet.
Alnylam Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops …
Full company profileAlnylam Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Alnylam Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 47.2M | 89.9M | 74.9M | 220M | 493M | 844M | 1.04B | 1.83B | 2.25B | 3.71B | 5.22B |
| Gross Profit | 47.2M | 89.9M | 73.1M | 195M | 415M | 704M | 869M | 1.52B | 1.92B | 3.04B | 4.06B |
| Operating Income | -425M | -500M | -815M | -939M | -828M | -709M | -785M | -282M | -177M | 502M | 1.13B |
| EBITDA | -409M | -487M | -754M | -885M | -697M | -662M | -927M | -258M | -179M | 631M | 1.26B |
| Net Income | -410M | -491M | -761M | -886M | -858M | -853M | -1.13B | -440M | -278M | 314M | 3.38B |
| EPS | -4.79 | -5.42 | -7.57 | -8.11 | -7.46 | -7.20 | -9.30 | -3.52 | -2.18 | 2.33 | 25 |
| Balance Sheet | |||||||||||
| Total Assets | 1.26B | 1.99B | 1.57B | 2.40B | 3.41B | 3.64B | 3.55B | 3.83B | 4.24B | 4.97B | 7.99B |
| Total Liabilities | 343M | 228M | 273M | 956M | 2.39B | 3.06B | 3.70B | 4.05B | 4.17B | 4.18B | 4.39B |
| Shareholders' Equity | 920M | 1.77B | 1.30B | 1.44B | 1.02B | 588M | -158M | -221M | 67.1M | 789M | 3.60B |
| Cash & Short-term Investments | 943M | 1.70B | 1.08B | 1.54B | 1.87B | 2.44B | 2.19B | 2.44B | 2.69B | 2.91B | 3.59B |
| Total Debt | 161M | 41.0M | 92.9M | 304M | 521M | 998M | 1.32B | 1.31B | 1.30B | 1.28B | 1.26B |
| Cash Flow | |||||||||||
| Operating Cash Flow | -308M | -383M | -563M | -278M | -615M | -642M | -541M | 104M | -8.31M | 524M | 649M |
| Capital Expenditure | 64.6M | 104M | 127M | 140M | 70.4M | 76.4M | 72.1M | 62.2M | 34.3M | 58.7M | 168M |
| Free Cash Flow | -372M | -487M | -690M | -419M | -685M | -718M | -613M | 41.9M | -42.6M | 465M | 481M |
| Ratios | |||||||||||
| ROE | -44.6% | -27.8% | -58.5% | -61.6% | -84.5% | -145.0% | - | - | -414.6% | 39.8% | 93.9% |
| ROA | -32.5% | -24.6% | -48.4% | -37.0% | -25.2% | -23.4% | -31.9% | -11.5% | -6.6% | 6.3% | 42.3% |
| Net Profit Margin | -869.6% | -545.9% | -1,016.6% | -403.2% | -174.1% | -101.0% | -109.0% | -24.1% | -12.4% | 8.4% | 64.8% |
| Debt to Equity | 0.18x | 0.02x | 0.07x | 0.21x | 0.51x | 1.70x | - | - | 19.32x | 1.62x | 0.35x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Alnylam Pharmaceuticals Inc dividends
Alnylam Pharmaceuticals Inc has not paid dividends in the last 9 fiscal years.
Who owns Alnylam Pharmaceuticals Inc
- Insiders 0.53%
- Institutions 99.47%
- Public & others 0.00%
- Shares outstanding 134M
- Free float 134M
Top funds holding ALNY.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| American Funds Growth Fd of Amer A | 8.96M | 6.69% | +17.58% | Sep 2026 |
| American Funds AMCAP A | 4.53M | 3.38% | +10.36% | Sep 2026 |
| T. Rowe Price Capital Appreciation | 4.51M | 3.37% | -0.73% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 4.25M | 3.17% | +0.19% | Sep 2026 |
| Vanguard MStar Mid Cap Index Instl | 2.87M | 2.14% | -0.78% | Sep 2026 |
| Invesco QQQ Trust | 2.78M | 2.08% | -0.10% | Oct 2026 |
| Vanguard Health Care Inv | 2.63M | 1.97% | +49.50% | Sep 2026 |
| Fidelity OTC | 2.10M | 1.57% | -1.86% | Aug 2026 |
| American Funds American Balanced A | 1.80M | 1.34% | +125.00% | Sep 2026 |
| Vanguard MStar Growth Index Investor | 1.76M | 1.32% | +9.44% | Sep 2026 |
| American Funds Invmt Co of Amer A | 1.61M | 1.20% | 0.00% | Sep 2026 |
| American Funds IS® Growth 1 | 1.48M | 1.11% | +23.85% | Sep 2026 |
| T. Rowe Price Mid-Cap Growth | 1.29M | 0.96% | 0.00% | Sep 2026 |
| Dodge & Cox Stock I | 1.23M | 0.92% | 0.00% | Sep 2026 |
| American Funds New Economy A | 1.11M | 0.83% | +53.94% | Sep 2026 |
| Vanguard MStar Mid Cap Growth ETF | 1.05M | 0.78% | +2.42% | Sep 2026 |
| iShares Biotechnology ETF | 1.04M | 0.78% | -0.32% | Oct 2026 |
| JNL/T. Rowe Price Capital Appreciation A | 1.02M | 0.76% | +107.54% | Sep 2026 |
| Strategic Advisers Fidelity US TtlStk | 923K | 0.69% | +3.94% | Sep 2026 |
| American Funds New Perspective A | 920K | 0.69% | -9.80% | Sep 2026 |
Top institutions holding ALNY.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 15.0M | 11.22% | +3.05% | Jun 2026 |
| Capital World Investors | 11.1M | 8.32% | +3.17% | Jun 2026 |
| BlackRock Inc | 10.9M | 8.14% | +4.43% | Jun 2026 |
| Capital Research Global Investors | 9.75M | 7.28% | +2.95% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 6.54M | 4.88% | +0.73% | Jun 2026 |
| Vanguard Capital Management, LLC | 6.03M | 4.50% | +1.39% | Jun 2026 |
| T. Rowe Price Investment Management,Inc. | 5.64M | 4.21% | +8.64% | Jun 2026 |
| Amvescap Plc. | 3.75M | 2.80% | -7.87% | Jun 2026 |
| State Street Corp | 3.56M | 2.65% | +7.01% | Jun 2026 |
| JPMorgan Chase & Co | 2.68M | 2.00% | -57.69% | Jun 2026 |
| Geode Capital Management, LLC | 2.64M | 1.97% | -0.92% | Jun 2026 |
| Baillie Gifford & Co Limited. | 2.44M | 1.82% | -2.16% | Jun 2026 |
| NORGES BANK | 2.27M | 1.70% | +0.85% | Jun 2026 |
| Wellington Management Company LLP | 2.11M | 1.58% | +9.01% | Jun 2026 |
| Orbis Allan Gray Ltd | 1.99M | 1.48% | +48.89% | Jun 2026 |
| Dodge & Cox | 1.96M | 1.46% | +1.35% | Jun 2026 |
| Two Sigma Investments LLC | 1.88M | 1.40% | -5.85% | Jun 2026 |
| American Century Companies Inc | 1.85M | 1.38% | +2.86% | Jun 2026 |
| ClearBridge Advisors, LLC | 1.26M | 0.94% | -7.12% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 1.15M | 0.86% | -19.79% | Jun 2026 |
Alnylam Pharmaceuticals Inc company profile
- Company name
- Alnylam Pharmaceuticals Inc
- Ticker
- ALNY.US
- Exchange
- USA Stocks
- Listed since
- May 28, 2004
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2,500
- Fiscal year end
- December
- Address
- 675 West Kendall Street, Cambridge, MA, United States, 02142
- Phone
- 617 551 8200
- Website
- alnylam.com
About Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Alnylam Pharmaceuticals Inc management
10- Dr. Yvonne L. Greenstreet M.B.A., M.D.CEO & Director · born 1963
- Dr. Phillip A. Sharp Ph.D.Co-Founder, Member of the Scientific Advisory Board · born 1945
- Mr. Jeffrey V. Poulton M.B.A.CFO & Executive VP · born 1968
- Mr. Bryan Andrew Supran J.D.Chief Legal Officer · born 1970
- Dr. Pushkal P. Garg M.D.Executive VP & Chief Research & Development Officer · born 1968
- Mr. Timothy J. MainesChief Technical Operations & Quality Officer
- Dr. Kevin Joseph Fitzgerald Ph.D.Executive VP, Chief Scientific Officer and Head of Early Research & Early Development · born 1968
- Mr. Joshua BrodskyVice President of Investor Relations
- Mr. Piyush Sharma J.D.Chief Ethics & Compliance Officer
- Ms. Sandra WaiteChief Communications Officer